Takeda pharmaceuticals bags award for innovation and enterprise leadership

0 131

The Center for Innovation and BioDesign (CIBioD) conferred Simon Gallagher of Takeda with the ‘Arogaya CIBioD innovation and enterprise leadership award’ at the Tech4Seva Summit. Takeda is an innovative value-based global biopharmaceutical company. It has been working to provide Indians access to potentially life-changing treatments and medicinal products.

The awarding body CIBioD) is an initiative of the Indian Council of Medical Research aimed at promoting research, innovation, and entrepreneurship in the Indian healthcare system.

On receiving the award, the general manager of Takeda India, Simon Gallagher, said, “I am honored to receive this award on behalf of Takeda. At Takeda, we believe in the power of public-private partnerships and innovations to broaden patient access to treatment and care in a sustainable way… With the same spirit, we recently conceptualized our ‘Blueprint for rare diseases’ initiative. We aim to go beyond identifying access gaps and their potential solutions and instead enable participants to commit to concrete plans of action to achieve these solutions. The honor motivates us to do more for healthcare systems of the world and aim to help patients lead the best quality of life possible.”

Simon indicated that they are planning to launch a dengue vaccine in India. Talking about their Budget impact model, Simon says that it helps patients to compare and understand the diseases better so they are able to make informed decisions. He also talked about an innovative personalized patient access program that is specifically tailored to support vulnerable patients.

Takeda came to India in 2011. It is present in 80 countries and employs 50,000 people. And they are recognized as a top employer in India. Takeda is highly focused on therapeutic areas, which are Oncology rare diseases, neuroscience, gastroenterology, plasma-derived therapies, and vaccines.

Watch the full event here:

Leave A Reply

Your email address will not be published.